Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 239.13 Million USD | 11.81% |
| 2022 | 213.88 Million USD | -5.94% |
| 2021 | 227.38 Million USD | 70.66% |
| 2020 | 133.24 Million USD | -32.84% |
| 2019 | 198.39 Million USD | 27.01% |
| 2018 | 156.2 Million USD | 13.02% |
| 2017 | 138.2 Million USD | 40.71% |
| 2016 | 98.22 Million USD | 67.29% |
| 2015 | 58.71 Million USD | 71.83% |
| 2014 | 34.16 Million USD | 85.59% |
| 2013 | 18.41 Million USD | 2278.68% |
| 2012 | 774 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 65.36 Million USD | 2.98% |
| 2024 Q2 | 73.14 Million USD | 11.9% |
| 2024 Q3 | 74.08 Million USD | 1.29% |
| 2023 Q3 | 59.53 Million USD | -1.26% |
| 2023 Q2 | 60.29 Million USD | 8.0% |
| 2023 FY | 239.13 Million USD | 11.81% |
| 2023 Q4 | 63.47 Million USD | 6.61% |
| 2023 Q1 | 55.82 Million USD | 3.38% |
| 2022 Q3 | 54.4 Million USD | -0.81% |
| 2022 Q4 | 54 Million USD | -0.74% |
| 2022 FY | 213.88 Million USD | -5.94% |
| 2022 Q1 | 50.61 Million USD | -10.21% |
| 2022 Q2 | 54.85 Million USD | 8.36% |
| 2021 Q2 | 60.33 Million USD | 17.53% |
| 2021 Q4 | 56.37 Million USD | -5.0% |
| 2021 Q3 | 59.34 Million USD | -1.65% |
| 2021 FY | 227.38 Million USD | 70.66% |
| 2021 Q1 | 51.33 Million USD | -4.3% |
| 2020 Q1 | 22.8 Million USD | -54.34% |
| 2020 Q2 | 9.89 Million USD | -56.64% |
| 2020 Q3 | 46.89 Million USD | 374.21% |
| 2020 Q4 | 53.64 Million USD | 14.38% |
| 2020 FY | 133.24 Million USD | -32.84% |
| 2019 Q4 | 49.94 Million USD | -1.69% |
| 2019 FY | 198.39 Million USD | 27.01% |
| 2019 Q3 | 50.8 Million USD | 0.15% |
| 2019 Q2 | 50.73 Million USD | 8.13% |
| 2019 Q1 | 46.91 Million USD | -0.09% |
| 2018 Q4 | 46.95 Million USD | 23.91% |
| 2018 FY | 156.2 Million USD | 13.02% |
| 2018 Q2 | 37 Million USD | 7.73% |
| 2018 Q1 | 34.34 Million USD | -7.22% |
| 2018 Q3 | 37.89 Million USD | 2.42% |
| 2017 Q4 | 37.02 Million USD | 6.7% |
| 2017 FY | 138.2 Million USD | 40.71% |
| 2017 Q1 | 30.72 Million USD | 8.34% |
| 2017 Q2 | 35.76 Million USD | 16.39% |
| 2017 Q3 | 34.69 Million USD | -2.99% |
| 2016 FY | 98.22 Million USD | 67.29% |
| 2016 Q2 | 24.19 Million USD | 21.16% |
| 2016 Q3 | 25.69 Million USD | 6.17% |
| 2016 Q1 | 19.97 Million USD | 19.72% |
| 2016 Q4 | 28.36 Million USD | 10.39% |
| 2015 FY | 58.71 Million USD | 71.83% |
| 2015 Q4 | 16.68 Million USD | 6.36% |
| 2015 Q3 | 15.68 Million USD | 8.37% |
| 2015 Q2 | 14.47 Million USD | 21.91% |
| 2015 Q1 | 11.87 Million USD | 28.71% |
| 2014 Q2 | 8.76 Million USD | 38.94% |
| 2014 Q3 | 9.88 Million USD | 12.79% |
| 2014 Q1 | 6.3 Million USD | 12.82% |
| 2014 Q4 | 9.22 Million USD | -6.64% |
| 2014 FY | 34.16 Million USD | 85.59% |
| 2013 Q3 | 5.58 Million USD | 22.18% |
| 2013 Q1 | 2.66 Million USD | 0.0% |
| 2013 Q2 | 4.57 Million USD | 71.95% |
| 2013 Q4 | 5.58 Million USD | 0.0% |
| 2013 FY | 18.41 Million USD | 2278.68% |
| 2012 FY | 774 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 98.92% |
| Allurion Technologies Inc. | 41.49 Million USD | -476.273% |
| Artivion, Inc. | 229.17 Million USD | -4.346% |
| Avanos Medical, Inc. | 379.7 Million USD | 37.02% |
| Butterfly Network, Inc. | 16.85 Million USD | -1318.7% |
| Butterfly Network, Inc. | 16.85 Million USD | -1318.7% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 83.293% |
| Boston Scientific Corporation | 9.89 Billion USD | 97.583% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -14535.006% |
| CONMED Corporation | 643.06 Million USD | 62.813% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 94.829% |
| Paragon 28, Inc. | 172.79 Million USD | -38.396% |
| Globus Medical, Inc. | 1.02 Billion USD | 76.562% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | 54.728% |
| Integer Holdings Corporation | 418.28 Million USD | 42.83% |
| Medtronic plc | 19.45 Billion USD | 98.771% |
| Nevro Corp. | 290.06 Million USD | 17.556% |
| Owlet, Inc. | 22.58 Million USD | -958.733% |
| Penumbra, Inc. | 682.64 Million USD | 64.969% |
| Vicarious Surgical Inc. | -1.85 Million USD | 12998.382% |
| Smith & Nephew plc | 3.7 Billion USD | 93.539% |
| Sonendo, Inc. | 10.72 Million USD | -2130.33% |
| STERIS plc | 2.23 Billion USD | 89.296% |
| Stryker Corporation | 13.05 Billion USD | 98.169% |
| Vapotherm, Inc. | 28.28 Million USD | -745.511% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 95.497% |